182 results on '"Visentin, Andrea"'
Search Results
2. Extended-wavelength diffuse reflectance spectroscopy dataset of animal tissues for bone-related biomedical applications
3. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia
4. Stochastic Dynamic Programming Heuristic for the (R, s, S) Policy Parameters Computation
5. Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors
6. Electricity Price Forecasting in the Irish Balancing Market
7. Road pavement health monitoring system using smartphone sensing with a two-stage machine learning model
8. Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines
9. Establishing the original order of the poems in Harward’s Almanac using paleography, codicology, X-ray fluorescence spectroscopy, and statistical analysis
10. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
11. Stochastic dynamic programming heuristic for the [formula omitted] policy parameters computation
12. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
13. Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD.
14. Focal adhesion kinase as a new player in the biology of oncohematological diseases: the starting evidence.
15. CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience.
16. Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax‐based regimens.
17. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
18. The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies
19. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
20. Computing optimal ([formula omitted]) policy parameters by a hybrid of branch-and-bound and stochastic dynamic programming
21. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
22. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)
23. Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience.
24. Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review.
25. When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario.
26. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments
27. Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course.
28. Demyelinating Polyradiculoneuropathy in Chronic Lymphocytic Leukemia: A Case Report on BTKis versus Venetoclax-Rituximab.
29. How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia.
30. p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formation.
31. CBA 2.0 Scale Primarie: Nuovi dati e criteri interpretativi per le problematiche depressive.
32. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort.
33. Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
34. The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia
35. Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL
36. Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients
37. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
38. Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
39. Focal adhesion kinase activation by calcium‐dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
40. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
41. p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes
42. Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia
43. Continuous venetoclax in treatment‐naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
44. Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response.
45. Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature.
46. Mutational Profile in 75 Patients With Anti--Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
47. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers
48. The added value of karyotype in predicting the need for therapy in chronic lymphocytic leukemia with 13q deletion.
49. Aberrant expression of CD10 and BCL6 in mantle cell lymphoma
50. Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.